性激素及靶向性激素治疗在系统性硬化症中的作用:系统文献综述
该系统综述检索了Pubmed、Embase、Web of Science和Cochrane图书馆数据库,最终纳入30篇文献,探讨性激素在系统性硬化症(SSc)发病机制中的作用、SSc患者性激素水平变化及靶向性激素治疗对疾病进程的影响。现有证据提示雌激素在SSc中可能具有促纤维化和血管舒张双重作用,但研究质量参差不齐且样本量小,尚无近期高质量试验评估靶向性激素治疗在SSc中的疗效。
要点
- 雌激素在SSc中可能兼具促纤维化和血管舒张作用。
- 女性SSc患者雄激素水平倾向低于健康对照,雌二醇倾向非显著升高。
- 尚无近期高质量试验评估靶向性激素治疗在SSc中的疗效。
核心结论
- 现有证据提示雌激素在SSc中可能具有促纤维化和血管舒张作用,但研究数量少、质量不一,需更多研究阐明其贡献程度。
研究设计与样本
- 系统文献综述,检索Pubmed、Embase、Web of Science和Cochrane图书馆数据库,共检索到300篇文章,最终纳入30篇。
主要发现
- 女性SSc患者与健康对照相比倾向有较低雄激素水平和非显著升高的雌二醇水平,男性SSc患者雌二醇水平升高而雄激素结果不一致。
- 绝经后皮肤评分似乎下降而肺动脉高压患病率似乎上升,激素替代治疗可能预防后者。
- 尚无近期高质量试验评估靶向性激素治疗在SSc中的疗效。
临床怎么用
- 对SSc患者评估性激素水平及绝经状态可能有助于理解疾病进展差异,但靶向性激素治疗尚无高质量证据支持常规应用。
局限性
- 纳入研究样本量小、研究设计异质性强、质量参差不齐,且缺乏近期高质量靶向性激素治疗试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pathophysiology of systemic sclerosis (SSc) is complex and elusive, however, considering the strong female preponderance and different clinical characteristics between men and women, a contribution of sex hormones has been proposed. OBJECTIVES: We undertook this systematic literature review to investigate: (1) the role played by male and female sex hormones in the pathogenesis of SSc; (2) how sex hormone levels change in SSc patients and how hormonal variations modify the progression of SSc; (3) the effect of therapies targeting sex hormones on the disease course. METHODS: A literature search was performed in Pubmed, Embase, Web of Science, and Cochrane library databases. Given the heterogeneity in study design, different quality assessment tools were applied where appropriate. RESULTS: We retrieved 300 articles and 30 were included in the review. The available evidence points to a fibrogenic, but also a vasodilatory, role of estrogens in SSc. With the limitation of small sample sizes, women with SSc tend to have lower levels of androgens and non-significantly higher levels of estradiol compared to healthy controls, while in men we found increased levels of estradiol and discordant results for androgens. After menopause the skin score seems to decrease and prevalence of pulmonary artery hypertension seems to rise, which might be prevented by the use of hormone replacement therapy. No recent high-quality trial evaluated the efficacy of hormone-targeting therapies in SSc. CONCLUSIONS: Few translational studies of varying quality evaluated the role of sex hormones in SSc showing possible profibrotic and vasodilatatory effects of estrogens, but more research is needed to elucidate the extent of this contribution. Insights on the influence of sex hormones, along with the availability of new compounds acting on estrogen pathways, might provide ideas for additional studies on the application of sex hormone-targeting therapies in SSc.
引用
- Ciaffi J, van Leeuwen NM, Schoones JW, et al. Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. Semin Arthritis Rheum. 2019. PMID: 31362894. doi:10.1016/j.semarthrit.2019.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。